APT Pharmaceuticals

About APT Pharmaceuticals

Founded in 2005, APT Pharmaceuticals is a clinical-stage drug development company headquartered in Burlingame, California. The firm was established by Dr. B. Lauren Charous to focus on creating inhaled therapeutics for inflammatory diseases and transplantation. The company directs its efforts toward repurposing well-characterized drugs for patient populations with significant unmet medical needs.

APT Pharmaceuticals has demonstrated a strong ability to secure capital, raising a total of $62.3 million over three funding rounds. Its first funding round occurred in July 2005, followed by a Series A-2 financing in September 2007 that brought in $22 million. The most recent round, a Series B in September 2008, raised $32.3 million and was led by Three Arch Partners. The company's investor base includes prominent institutional investors such as Great Point Partners, InterWest Partners, Vivo Ventures, Versant Ventures, Charter Life Sciences, and Research Corporation Technologies.

The company's core business revolves around its drug development pipeline. Its lead program focuses on an inhaled cyclosporine solution (CIS), known as Pulminiq, designed for the prevention and treatment of chronic rejection in lung transplant recipients. This initiative has progressed to a multi-center Phase III clinical trial to evaluate its efficacy. The business model is centered on advancing its product candidates through the clinical trial process to address critical underserved markets, thereby creating value.